NEW YORK (GenomeWeb News) — A Blue Cross and Blue Shield Medical Advisory Panel has decided that Genomic Health’s Oncotype DX assay meets criteria set by the insurance company’s Technology Evaluation Center as a diagnostic for certain breast cancers, Genomic Health said today.
 
At a meeting last month the advisory panel concluded that the test meets its criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer, Genomic Health said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.